PMID- 26724663
OWN - NLM
STAT- MEDLINE
DCOM- 20160808
LR  - 20181202
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 85
IP  - 1
DP  - 2016 Jan
TI  - Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung 
      cancer patients: Influence of mathematical models on early prediction 
      capabilities for treatment response and recurrence after chemoradiotherapy.
PG  - 176-186
LID - S0720-048X(15)30155-8 [pii]
LID - 10.1016/j.ejrad.2015.11.009 [doi]
AB  - PURPOSE: To determine the capability and influence of the mathematical method on 
      dynamic contrast-enhanced (CE-) perfusion area detector CT (ADCT) for early 
      prediction of treatment response as well as progression free and overall survival 
      (PFS and OS) of non-small cell lung cancer (NSCLC) patients treated with 
      chemoradiotherapy. MATERIALS AND METHODS: Sixty-six consecutive stage III NSCLC 
      patients underwent dynamic CE-perfusion ADCT examinations, chemoradiotherapy and 
      follow-up examinations. Response Evaluation Criteria in Solid Tumors (RECIST) 
      criteria were used to divide all patients into responders and non-responders. 
      Differences in each of the indices for all targeted lesions between measurements 
      obtained 2 weeks prior to the first and the third course of chemotherapy were 
      determined for all patients. ROC analyses were employed to determine the 
      capability of perfusion indices as markers for distinguishing RECIST responders 
      from non-responders. To evaluate their capability for early prediction of 
      therapeutic effect, OS of perfusion index-based responders and non-responders 
      were compared by using the Kaplan-Meier method followed by log-rank test. 
      RESULTS: Area under the curve (Az) for total perfusion by means of the dual-input 
      maximum slope method was significantly larger than that of pulmonary arterial 
      perfusion using the same method (p=0.007) and of perfusion with the single-input 
      maximum slope method (p=0.007). Mean OS demonstrated significantly difference 
      between responder- and non-responder groups for total perfusion (p=0.02). 
      CONCLUSION: Mathematical models have significant influence on assessment for 
      early prediction of treatment response, disease progression and overall survival 
      using dynamic CE-perfusion ADCT for NSCLC patients treated with 
      chemoradiotherapy.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Ohno, Yoshiharu
AU  - Ohno Y
AD  - Advanced Biomedical Imaging Research Center, Kobe University Graduate School of 
      Medicine, Kobe, Japan; Division of Functional and Diagnostic Imaging Research, 
      Department of Radiology, Kobe University Graduate School of Medicine, Kobe, 
      Japan. Electronic address: yosirad@kobe-u.ac.jp.
FAU - Koyama, Hisanobu
AU  - Koyama H
AD  - Division of Radiology, Department of Radiology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Fujisawa, Yasuko
AU  - Fujisawa Y
AD  - Toshiba Medical Systems Corporation, Otawara, Japan.
FAU - Yoshikawa, Takeshi
AU  - Yoshikawa T
AD  - Advanced Biomedical Imaging Research Center, Kobe University Graduate School of 
      Medicine, Kobe, Japan; Division of Functional and Diagnostic Imaging Research, 
      Department of Radiology, Kobe University Graduate School of Medicine, Kobe, 
      Japan.
FAU - Seki, Shinichiro
AU  - Seki S
AD  - Division of Radiology, Department of Radiology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Sugihara, Naoki
AU  - Sugihara N
AD  - Toshiba Medical Systems Corporation, Otawara, Japan.
FAU - Sugimura, Kazuro
AU  - Sugimura K
AD  - Division of Radiology, Department of Radiology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151110
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
RN  - 0 (Contrast Media)
SB  - IM
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*therapy
MH  - Chemoradiotherapy
MH  - *Contrast Media
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lung/*diagnostic imaging
MH  - Lung Neoplasms/diagnostic imaging/*therapy
MH  - Male
MH  - Models, Theoretical
MH  - Neoplasm Recurrence, Local/*diagnostic imaging
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - ROC Curve
MH  - Radiographic Image Enhancement
MH  - Reproducibility of Results
MH  - Tomography, X-Ray Computed/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CT
OT  - Chemoradiotherapy
OT  - Non-small cell lung cancer
OT  - Perfusion
OT  - Therapeutic effect
EDAT- 2016/01/03 06:00
MHDA- 2016/08/09 06:00
CRDT- 2016/01/03 06:00
PHST- 2015/07/19 00:00 [received]
PHST- 2015/10/23 00:00 [revised]
PHST- 2015/11/04 00:00 [accepted]
PHST- 2016/01/03 06:00 [entrez]
PHST- 2016/01/03 06:00 [pubmed]
PHST- 2016/08/09 06:00 [medline]
AID - S0720-048X(15)30155-8 [pii]
AID - 10.1016/j.ejrad.2015.11.009 [doi]
PST - ppublish
SO  - Eur J Radiol. 2016 Jan;85(1):176-186. doi: 10.1016/j.ejrad.2015.11.009. Epub 2015 
      Nov 10.